



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$13.35
Change (%)	0.00 (0.00%)
Volume	1
52 Week Low	\$4.55
Market Cap	\$624,449,681
Rolling EPS	-0.65
PE Ratio	0
Shares Outstanding	46,775,257



Data as of February 22, 2018 4:00 p.m. ET

Recent Press Releases & Upcoming Events

February 21, 2018
Abeona Therapeutics Announces
Upcoming Conference Participation

There are currently no events scheduled.

February 12, 2018
Abeona Therapeutics Receives FDA
Orphan Drug Designation for ABO-202
Gene Therapy Program in Infantile Batten
Disease

February 8, 2018
Abeona Therapeutics Reports Top-Line
Data from Phase 1/2 Gene Therapy Trial
in MPS IIIA

SEC Filings

Corporate Governance

Filing Date	Form
February 14, 2018	SC 13G/A
February 14, 2018	SC 13G/A
February 14, 2018	SC 13G/A
February 14, 2018	SC 13G/A

Data provided by Nasdaq. Minimum 15 minutes delayed.